United States Patent 6,531,141: What Do the Claims Cover and Where Is the Competitive Patent Thicket?

US Drug Patent 6,531,141 is directed to topical oil-in-water emulsions for delivering tretinoin at defined low concentrations using a specific emulsion architecture built from (1) caprylic/capric triglyceride, (2) defined polyethylene glycol ethers of C10-C30 fatty alcohols (two classes), (3) optional fatty acid and paired fatty alcohols, and (4) a high-water continuous phase. Dependent claims tighten this into specific preservative/antioxidant/chelating and rheology setups (xanthan gum, parabens, benzyl alcohol, BHT, edetate disodium, and a listed conditioning ingredient “Chemoderm 6401B”). Method claims then apply the compositions to skin conditions including acne, photodamaged skin, wrinkles, mottled hyperpigmentation, tactile roughness, and yellowing of facial skin.

What matters for freedom-to-operate is that the independent claim set is formulation-first (not device- or use-limited to a particular dosing regimen), and it uses numeric ranges for multiple excipient classes that can be engineered around only if competitors can move the formulation outside the claimed compositional “grid.”

What Is the Claim Scope: Core Independent Coverage vs Tight Formulation Locks?

Claim 1 (Independent): Composition-of-matter for a broad emulsion scaffold

Claim 1 covers an oil-in-water emulsion with the following compositional constraints (all % by weight):

Tretinoin: 0.001% to 1%
Oil phase structurant: caprylic/capric triglyceride: 5% to 20%
Nonionic PEG ether (high MW class): C30-C100 polyethylene glycol ether of a C10-C30 fatty alcohol: 1% to 10%
Nonionic PEG ether (low MW class): C4-C30 polyethylene glycol ether of a C10-C30 fatty alcohol: 0.1% to 5%
Optional fatty acid: C10-C30 fatty acid: 0% to 10%
Fatty alcohol pair:
- first C10-C30 fatty alcohol: 1% to 10%
- second C10-C30 fatty alcohol: 0% to 10%
Continuous phase: water: 50% to 90%

Interpretation for competitive design: this is a wide “composition-of-matter” but it is still highly constrained by requiring:

the exact oil ingredient class (caprylic/capric triglyceride),
two PEG-ether surfactant families with different ethoxylate/molecular range endpoints, and
a specific water/oil envelope plus at least one fatty alcohol.

Claim 2 (Dependent): Adds formulation package for stability/handling

Claim 2 adds to Claim 1:

Xanthan gum: 0.1% to 1%
Preservative: 0.001% to 1%
Antioxidant: 0.001% to 1%
Chelating agent: 0.001% to 1%
Fragrance: 0% to 1%

This increases enforceability against “same core emulsifier system” but with typical formulation additives.

Claim 3 (Dependent): Narrows PEG surfactant and defines an explicit preservative set and Chemoderm option

Claim 3 specifies a particular embodiment:

Tretinoin: 0.001% to 1%
Caprylic/capric triglyceride: 5% to 20%
Steareth-20: 1% to 10%
Steareth-2: 0.1% to 5%
Stearic acid: 0% to 10%
Cetyl alcohol: 1% to 10%
Stearyl alcohol: 1% to 10%
Water: 50% to 90%
Xanthan gum: 0.1% to 1%
Preservatives: mixture of propylparaben and methylparaben at 0.001% to 1%, plus benzyl alcohol at 0.1% to 5%
Antioxidant: butylene hydroxytoluene 0.001% to 1%
Chelator: edetate disodium 0.001% to 1%
Conditioning ingredient: Chemoderm 6401B 0% to 1%

This is a much more enforceable “real-world recipe” than Claim 1’s functional ranges.

Claims 4-8: Tight numeric embodiments that function like formulation “snapshots”

Claim 4 locks a specific ratio set (still “comprises”):
- Tretinoin 0.01% to 1%
- Caprylic/capric triglyceride 10%
- Steareth-20 4%
- Steareth-2 0.8%
- Stearic acid 0% to 4%
- Cetyl alcohol 4% to 6%
- Stearyl alcohol 3% to 6%
- Water 72%
- plus Claim 5 preservative/antioxidant/chelලාtor + Chemoderm constraints
Claim 6 uses “consisting essentially of” (material limitation: allows only ingredients that do not materially affect basic and novel characteristics; the claim language here is explicit).
- It hard-codes:
- tretinoin 0.01% to 1%
- caprylic/capric triglyceride 10%
- steareth-20 4%
- steareth-2 0.8%
- stearic acid 0% to 4%
- cetyl alcohol 4% to 6%
- stearly alcohol 3% to 6%
- water 72%
- xanthan gum 0.3%
- propylparaben 0.1%
- methylparaben 0.2%
- benzyl alcohol 1%
- BHT 0.1%
- edetate disodium 0.05%
- Chemoderm 6401B 0% to 0.01%
Claim 7 uses “consisting of” (stricter: excludes additional ingredients beyond what’s listed).
- Hard-codes:
- stearic acid 4%
- cetyl alcohol 4%
- stearly alcohol 3%
- Chemoderm 6401B 0.01%
- plus fixed xanthan, parabens, benzyl alcohol, BHT, edetate disodium
Claim 8 uses “consisting of” but with alternate specific fatty alcohol set:
- cetyl alcohol 5%, stearly alcohol 5%
- Omits Chemoderm and includes only BHT and edetate disodium as stability package items.

Practical impact: a competitor can’t avoid infringement by changing only tretinoin strength if the recipe hits one of the “consisting of/consisting essentially of” embodiments. But a competitor can often avoid by moving at least one of the tightly fixed components (e.g., caprylic/capric triglyceride level, steareth-2 at 0.8%, or the exact preservative pattern) outside the specified points/ranges.

What Do the Tretinoin-Strength Dependent Claims Add?

Claims 9-14 and 21-26 simply tie the formulation embodiments to specific tretinoin percentages (again, % by weight):

Claim 9: Claim 1 with tretinoin 0.02%
Claim 10: Claim 7 with tretinoin 0.02%
Claim 11: Claim 8 with tretinoin 0.02%
Claim 12: Claim 1 with tretinoin 0.05%
Claim 13: Claim 7 with tretinoin 0.05%
Claim 14: Claim 8 with tretinoin 0.05%

Method equivalents mirror those values (Claims 21-26 depend on method claims 18-20 and lock tretinoin at 0.02% or 0.05%).

What Is Covered on Methods: Skin Conditions and Medical Use Claims

Claim 15 (Independent method): Broad condition list using Claim 1 emulsion scaffold

A method claim for mitigating skin conditions in humans selected from:

acne
photodamaged skin
wrinkles
mottled hyperpigmentation
tactile roughness
yellowing of facial skin

Method is topical administration of the Claim 1 emulsion (with its broad emulsion constraints).

Claims 16-17 (Dependent methods): lock to “consisting” embodiment compositions

Claim 16 uses the consisting of emulsion of Claim 7 (including Chemoderm 6401B at 0.01%).
Claim 17 uses the consisting of emulsion of Claim 8 (no Chemoderm; fixed cetyl/stearly alcohol set).

Claims 18-20: Narrow to “fine wrinkles”

Claim 18 depends from Claim 15 and specifies fine wrinkles.
Claim 19 depends from Claim 16 and specifies fine wrinkles.
Claim 20 depends from Claim 17 and specifies fine wrinkles.

Claims 21-26: Fine wrinkles + fixed tretinoin strength

Each depends on fine wrinkle methods (claims 18-20) and locks the emulsion’s tretinoin content at 0.02% or 0.05%.

Key scope point: these are use claims tied to the same compositional recipes. That shifts infringement risk: a party making a non-claimed formulation can still be trying to practice free therapeutic use, but it won’t reach these method claims unless the administration uses the claimed emulsion composition.

How Does the Claim Drafting Create a Patent “Grid” Competitors Must Break?

Below is the compositional “grid” created by Claim 1 (broad) and tightened by Claims 3-8 (specific).

Must-hit elements for Claim 1 category (oil-in-water emulsion)

To read on Claim 1, a product must be an oil-in-water emulsion with:

Tretinoin within 0.001% to 1%
Caprylic/capric triglyceride at 5% to 20%
Two PEG-ether surfactant systems:
- C30-C100 PEG ether of C10-C30 fatty alcohol at 1% to 10%
- C4-C30 PEG ether of C10-C30 fatty alcohol at 0.1% to 5%
At least one fatty alcohol (the “first C10-C30 fatty alcohol” must be 1% to 10%)
Water at 50% to 90%

“Real formulation” locks in Claims 3-8

A product that uses:

Steareth-20 and Steareth-2 in the specified amounts,
cetyl alcohol and stearly alcohol as the defined fatty alcohols,
typical preservative package (parabens + benzyl alcohol) with BHT or butylene hydroxytoluene and edetate disodium, and
xanthan gum, will be pulled into Claim 3 or the tight embodiments (4-8).

Patent Landscape: What Other Patents Likely Matter Around This Family?

The landscape for tretinoin topical emulsions clusters around three themes:

Tretinoin formulations and delivery systems (vehicle, emulsifier packages, stabilizers, preservatives, antioxidants, penetration-related excipients).
Nonionic surfactant and fatty-alcohol/PEG-ether system design for emulsion stability and microstructure control.
Specific therapeutic uses for acne, photodamage, wrinkles, and hyperpigmentation.

Within that ecosystem, US 6,531,141 contributes a specific “signature”:

caprylic/capric triglyceride paired with two PEG ether surfactants defined by chain-length ranges,
plus defined fatty alcohols and optional fatty acid,
and an explicit stabilizer/preservative package including xanthan gum, parabens + benzyl alcohol, BHT/butylene hydroxytoluene, and edetate disodium, with an optional conditioning ingredient Chemoderm 6401B.

However, without retrieving the full bibliographic metadata (assignee, filing date, continuation/divisional status, and cited prior art) and without scanning live patent family records, it is not possible to produce an accurate, citation-backed “who-owns-what” map of:

co-pending siblings,
blocking continuations,
prosecution history,
or the most relevant earlier patents that define the prior-art boundary for the PEG-ether/caprylic triglyceride emulsion space.

Accordingly, the analysis below focuses on scope-based competitive implications rather than naming specific competitor patents or assignees.

Competitive Implications: Where Do Infringement Risks Concentrate?

Highest risk product profiles

Risk concentrates where a competitor product:

uses caprylic/capric triglyceride in the 5% to 20% band,
deploys steareth-20 and steareth-2 (or chemically equivalent PEG ether classes) within the claimed bands,
includes cetyl alcohol and stearyl alcohol as the defined fatty alcohols,
and includes a typical cosmetic/dermatology stability kit matching Claim 3 or Claim 5/6/7/8.

High-leverage design changes (conceptual, not legal advice)

To move outside claim scope, a product generally must avoid at least one of the claim’s essential elements:

eliminate or replace caprylic/capric triglyceride as the specified oil fraction,
replace one of the PEG ether surfactant systems so it falls outside the two-range architecture,
or use a fatty-alcohol system that does not satisfy both the “first” and “second” fatty alcohol constraints.

For “consisting of” claims (7 and 8), the path to non-infringement also includes avoiding any listed ingredient outside the exact set (including Chemoderm 6401B for Claim 7 or its omission for Claim 8).

Claim-by-Claim Landscape Pressure Points (Summary Table)

Claim	Legal structure	What tightens scope	Practical infringement hook
1	“comprising”	numeric composition grid for core emulsifier architecture	broad emulsion match required across oil/PEG/water/fatty alcohol ranges
2	dependent	stability/rheology add-ins via ranges	common to many finished products, but must still stay within ranges
3	dependent	explicit surfactants (steareth-20/2), preservative system, BHT/butylene hydroxytoluene, edetate	pulls in “real recipe” products
4	dependent	locks specific point values (caprylic/capric triglyceride 10%, steareth-20 4%, steareth-2 0.8%, water 72%)	difficult to design around without changing the recipe
5	dependent	fixes preservative/antioxidant/chelators and Chemoderm ceiling	stability package becomes a key differentiator
6	“consisting essentially of”	locks the full recipe with narrow Chemoderm range	strong formulation lock with limited allowable additives
7	“consisting of”	fully enumerated recipe, including Chemoderm 0.01% and exact fatty alcohol values	exact-match requirement increases predictability for FTO screening
8	“consisting of”	enumerated recipe variant (no Chemoderm) with defined fatty alcohol points	exact-match requirement; variant space for design-arounds
9-14	dependent	fixed tretinoin strengths added onto broad/specific compositions	strength alone does not avoid if base recipe remains within claim

Key Takeaways

US 6,531,141 is formulation-centric: the protected subject matter is an oil-in-water emulsion with numerically defined excipient architecture and tretinoin at low concentrations.
Independent coverage (Claim 1) requires a specific combination of caprylic/capric triglyceride, two PEG ether surfactant classes, defined fatty alcohols, and a water/oil envelope.
Dependent claims (3-8) convert that scaffold into specific recipes using steareth-20/steareth-2, cetyl/stearly alcohol, xanthan gum, parabens + benzyl alcohol, BHT/butylene hydroxytoluene, and edetate disodium, with Chemoderm 6401B as a differentiator.
“Consisting essentially of” and “consisting of” claims (6-8) materially increase enforceability against near-identical products by limiting allowable deviations from the enumerated ingredient set and, for Claim 7, requiring Chemoderm 6401B at 0.01%.
Method claims (15-20) and strength add-ons (21-26) tie therapeutic use to the same formulation constraints, including fine wrinkles and specified tretinoin strengths (0.02% and 0.05%).

FAQs

1) Does US 6,531,141 protect the method of using tretinoin generally for acne or wrinkles?

No. It protects methods of mitigating named skin conditions only when the treatment uses the claimed emulsion compositions. The therapeutic use is tethered to the formulation structure in Claims 1, 7, or 8 depending on the method claim.

2) If a product has tretinoin but uses a different oil phase than caprylic/capric triglyceride, does it avoid the patent?

It will fall outside the scope of Claim 1’s requirement for caprylic/capric triglyceride at 5% to 20% (and the fixed 10% in the tighter embodiments). Avoidance depends on exact formulation match, but changing the oil ingredient away from that defined material is a central design lever.

3) Are steareth-20 and steareth-2 required for infringement?

They are explicitly required for the tighter embodiments (Claim 3 and the specific point-locked claims), and they map onto the generic “PEG ether of fatty alcohol” structure in Claim 1. A formulation that does not use those exact surfactants could still infringe if it uses chemically equivalent C30-C100 and C4-C30 PEG ether classes in the claimed bands, but the most predictable match is where steareth-20/2 are used as stated.

4) What ingredient most clearly distinguishes Claim 7 from Claim 8?

Chemoderm 6401B. Claim 7 includes Chemoderm 6401B at 0.01% under “consisting of,” while Claim 8 omits Chemoderm and instead lists only BHT and edetate disodium in the stability/chelating package.

5) Do the tretinoin strength sub-claims (0.02% and 0.05%) expand the protection beyond the base formulation?

No. They narrow infringement to formulations that already meet the base emulsion structure of the referenced claims and then specify tretinoin at 0.02% or 0.05%.

References

[1] United States Patent 6,531,141, “Oil-in-water emulsion containing tretinoin,” claims 1-26 (as provided in the prompt).

Details for Patent: 6,531,141

Summary for Patent: 6,531,141